Pacer BioThreat Strategy ETF
VIRS

$37.87

1.24%

Market Cap: 3.79M

0

Funds holding %

of 6,702 funds

–

Analysts bullish %

–

News positive %

Fund manager confidence

Based on 2024 Q1 SEC filings by fund managers ($100M+ AUM)

200% more first-time investments, than exits

New positions opened: 2 | Existing positions closed: 0

50% more funds holding

Funds holding: 4 [Q4 2023] → 6 (+2) [Q1 2024]

11% more capital invested

Capital invested by funds: $1.6M [Q4 2023] → $1.79M (+$183K) [Q1 2024]

0.14% less ownership

Funds ownership: 49.65% [Q4 2023] → 49.51% (-0.14%) [Q1 2024]

67% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 3

See Fund Rankings

Research analyst outlook

We haven’t received any recent analyst ratings for VIRS.

See Analyst Rankings

Financial journalist opinion

Zacks Investment Research

Netflix ETFs to Buy on the Dip Post Solid Q1 Earnings

Netflix (NFLX) topped both earnings and revenue estimates and delivered its strongest first-quarter customer additions since the pandemic. However, it issued disappointing second-quarter revenue guidance, which dragged the stock down.

Netflix ETFs to Buy on the Dip Post Solid Q1 Earnings

Zacks Investment Research

What Lies in Store for Netflix ETF in Q1 Earnings?

Netflix has risen about 26% over the past three months and has a reasonable chance to beat earnings estimates.

What Lies in Store for Netflix ETF in Q1 Earnings?

See News Rankings